Pathogenesis and therapeutic strategy in platinum resistance lung cancer.

2021 
Platinum compounds (cisplatin and carboplatin) represent the most active anticancer agents in clinical use both of lung cancer in mono-and combination therapies. However, platinum resistance limits its clinical application. It is necessary to understand the molecular mechanism of platinum resistance, identify predictive markers, and develop newer, more effective and less toxic agents to treat platinum resistance in lung cancer. Here, it summarizes the main molecular mechanisms associated with platinum resistance in lung cancer and the development of new approaches to tackle this clinically relevant problem. Moreover, it could lead to the development of more effective treatment for refractory lung cancer in future.
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    164
    References
    0
    Citations
    NaN
    KQI
    []